Abstract
Background Despite growing awareness of the crucial role of the coronary vasculature in cardiovascular health and disease, diagnosing coronary microvascular disease (CMVD) remains challenging because it often requires advanced cardiac imaging that are available at only a few centers. For example, perfusion positron emission tomography (PET) allows for the quantification of the myocardial blood flow (MBF) and, thus, the calculation of the MBF reserve (MBFR), which is the ratio of MBF under rest conditions and MBF under hyperemic or stress conditions. In the absence of obstructive coronary artery disease, MBFR is a measure of CMVD. However, the availability of perfusion PET is limited. Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) is an angiography-based measure of coronary flow that has been proposed, but not well established, as a measure of CMVD. We aim to demonstrate a relationship between TFC and MBFR and to establish cut-off measures from clinical coronary angiograms for the diagnosis of CMVD.
Methods We identified a cohort of 123 patients (age 58 +/− 12.1, 63% female, 41% Caucasian) who had no obstructive coronary artery disease and had undergone perfusion PET stress testing and clinical coronary angiography for clinical indications. We compared TFC for each coronary territory with regional perfusion PET parameters using linear regression modeling. We then used two mathematical models of the coronary circulation to understand the relationship between these parameters. We performed ROC analysis to determine the ability of TFC to diagnose CMVD, defined as global MBFR < 2.
Results There is a very tight sex-dependent correlation between TFC and MBFR, but no association between resting coronary flow and TFC and only a weak association between stress coronary flow and TFC. Mathematical modeling of the coronary circulation highlights an uncoupling between TFC and flow in larger vessels where TFC is measured, providing a likely explanation for the surprising empiric result. ROC analysis shows TFC as an excellent measure of CMVD in women (AUC 0.84-0.89) and establishes TFC cutoffs.
Conclusions TFC from clinical coronary angiograms reflects coronary microvascular function in a sex-dependent manner and performs well in identifying women with CMVD.
What is new?Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) is highly correlated with myocardial blood flow reserve (MBFR), which reflects coronary vasodilatory potential, in patients without obstructive coronary artery disease.
Computational modeling establishes how the relationship between TFC and MBFR can exist.
TFC performs much better in women than in men for the diagnosis of coronary microvascular disease (CMVD) and thresholds for the diagnosis of CMVD with TFC are identified.
What are the clinical implications?TFC from clinical coronary angiograms can be used to assess CMVD in women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH K08HL136890, Burroughs Wellcome Fund, and Doris Duke Charitable Foundation (MAG) and NIH R01HL149801 (MAG, SDM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Pennsylvania gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
